[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-stage":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":38,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100545979",false,"NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",true,"ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[25,26,27,28,29,30,31,32,33,34,35,36,37],"Pancreatic Cancer","Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Resectable","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III","Pancreatic Cancer, Adult","Pancreatic Cancer Non-resectable",[39,40,41,42,43],"Micro RNA","Exosome","Cell free","Early detection","Screening","RECRUITING","2025-12-17",{"date":47,"type":48},"2025-12-19","ACTUAL",{"date":50,"type":48},"2023-03-15",{"date":52,"type":21},"2026-06-18",{"name":54,"class":55},"City of Hope Medical Center","OTHER",11,{"id":58,"slug":4,"hasResults":10,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100565792","NCT06646783","Phase IIT Trial of SNA014","Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET\u002FCT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer","Inclusion Criteria:\n\n* Age range of 18 to 75 years old (including boundary values);\n* Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);\n* Diagnosed G\u002FGEJ adenocarcinoma and pancreatic cancer;\n* Gastroscopy\u002FCT\u002FMRI\u002FPET-CT examination results within the past month (if any);\n* Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).\n\nExclusion Criteria:\n\n* Merge patients with other clearly diagnosed malignant tumors:\n* Uncontrolled severe infections or individuals with other serious illnesses;\n* Those with an expected survival period of less than or equal to three months;\n* Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;\n* investigators determine that patients who are not suitable to participate in this study;","75 Years",{"count":65,"type":21},28,"INTERVENTIONAL",[68],"EARLY_PHASE1","68Ga labeled Claudin 18.2 contrast agent combined with PET\u002FCT for gastric or gastroesophageal junction",[71,72,31],"Adenocarcinoma of the Stomach","Adenocarcinoma of GE Junction","NOT_YET_RECRUITING","2024-10-15",{"date":76,"type":48},"2024-10-17",{"date":78,"type":21},"2024-10-20",{"date":80,"type":21},"2025-11-20",{"name":82,"class":83},"SmartNuclide Biopharma","INDUSTRY",1,""]